Q-omics provides the consensus-scored PRPF39 profile across patient tissues and cancer cell-line models. PRPF39 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PRPF39 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PRPF39 protein abundance shows 22,084 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where PRPF39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF39 survival associations across molecular data types. PRPF39 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF39 RNA expression–survival associations across cancer types. High PRPF39 expression shows unfavorable associations in LIHC, ACC, KICH, KIRC and ESCA, but favorable associations in UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PRPF39 RNA expression.
This table summarizes PRPF39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRPF39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF39 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, BLCA and COAD. The HNSC box plot shows higher PRPF39 RNA expression in tumor versus normal tissue (log2 FC = +0.633, t-test p < 0.001).
This table shows molecular features associated with PRPF39 in patient tissues and cancer cell lines. In patient samples, PRPF39 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPF39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
